Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.

Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, Myer VE, Ettenberg SA, Schlegel R, Sellers WR, Huet HA, Lehár J.

PLoS One. 2015 Sep 17;10(9):e0138486. doi: 10.1371/journal.pone.0138486. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0146635.

2.

CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY.

Cancer Res. 2008 Jul 1;68(13):5335-44. doi: 10.1158/0008-5472.CAN-07-6209.

3.

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.

Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, Zafari M, Kowal C, Yang G, Royo A, Jensen M, Dombrecht B, Meerschaert KR, Kolkman JA, Cromie KD, Mosher R, Gao H, Schuller A, Isaacs R, Sellers WR, Ettenberg SA.

MAbs. 2014;6(6):1560-70. doi: 10.4161/19420862.2014.975099.

4.

HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.

Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR.

Cancer Biol Ther. 2012 Aug;13(10):946-55. doi: 10.4161/cbt.20952. Epub 2012 Aug 1.

5.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.

Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.

Neurosurg Focus. 2002 Sep 15;13(3):ecp1.

PMID:
15844877
6.

Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.

Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.

Prostate. 2006 Jun 15;66(9):987-95.

PMID:
16541419
7.

A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.

James MA, Seibel WL, Kupert E, Hu XX, Potharla VY, Anderson MW.

Anticancer Drugs. 2015 Jun;26(5):518-30. doi: 10.1097/CAD.0000000000000213.

PMID:
25646742
8.

Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E.

Br J Cancer. 2010 Feb 16;102(4):754-64. doi: 10.1038/sj.bjc.6605545. Epub 2010 Jan 19.

9.

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.

Kang Z, Goldstein SD, Yu Y, Meltzer PS, Loeb DM, Cao L.

Br J Cancer. 2015 Sep 15;113(6):894-901. doi: 10.1038/bjc.2015.298. Epub 2015 Aug 20.

10.

Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y.

Neuro Oncol. 2010 Jul;12(7):687-700. doi: 10.1093/neuonc/nop069. Epub 2010 Feb 11.

11.
12.

Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.

Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T.

Mol Cancer Res. 2008 Dec;6(12):1852-60. doi: 10.1158/1541-7786.MCR-08-0012.

14.
16.
17.

Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.

Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K.

Exp Hematol. 2010 Oct;38(10):885-95. doi: 10.1016/j.exphem.2010.06.014. Epub 2010 Jul 27.

PMID:
20670671
18.

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.

Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S.

Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10.

19.

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.

Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B.

Mol Cancer Ther. 2007 Apr;6(4):1387-99.

Supplemental Content

Support Center